Anticoagulation in Patients With Venous Thromboembolism and Cancer

Study Summary

This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs.

Conditions

Neoplasms Embolism

Interventions / Drugs

Apixaban Rivaroxaban Edoxaban Dabigatran VKA LMWH

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment1 participants

Primary Completion—

Lead SponsorPfizer

Data Retrieved2026-04-11 02:55:53.189527+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.